This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2022-2025.
Company Filing History:
Years Active: 2022-2025
Title: The Innovations of Niksa Kastrapeli
Introduction
Niksa Kastrapeli is a notable inventor based in Wellesley, MA (US). He has made significant contributions to the field of biopharmaceuticals, particularly in the development of bispecific antibodies. With a total of 2 patents, Kastrapeli's work is focused on addressing critical health issues.
Latest Patents
Kastrapeli's latest patents include bispecific antibodies against plasma kallikrein and factor XII. These antibodies are designed to bind to plasma kallikrein (pKal) and Factor XII, providing methods for producing and utilizing these bi-specific antibodies in treating diseases or disorders associated with the contact system, such as hereditary angioedema or thrombosis.
Career Highlights
Kastrapeli is currently employed at Takeda Pharmaceutical Company Limited, where he continues to innovate in the field of therapeutics. His work is instrumental in advancing treatments that can significantly improve patient outcomes.
Collaborations
Some of his notable coworkers include Stephen R Comeau and Andrew Nixon. Their collaborative efforts contribute to the success of the projects they undertake together.
Conclusion
Niksa Kastrapeli's contributions to the field of biopharmaceuticals through his patents and work at Takeda Pharmaceutical Company Limited highlight his role as an influential inventor. His innovations in bispecific antibodies are paving the way for new treatments in medicine.